Profound Medical Corp. remains rated Sell due to persistent competitive pressures, missed growth promises, and deteriorating financials. PROF's recent 20% stock spike followed news of a Dallas Medical ...

Profound Medical (PROF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

61% were treated for prostate cancer only, 28% were hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”), 10% were salvage, and 1% were men with BPH only; For ...

TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

Profound Medical PROF shares soared 9.5% in the last trading session to close at $8.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement ...

Israel-based Zebra Medical Vision, a machine-learning imaging analytics company, has announced the launch of new platform that allows people upload and receive analysis of their medical scans from ...